Company Profile
Prestige BioPharma Limited, a biopharmaceutical company provides the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer.
Its portfolio also includes Bevacizumab biosimilar for the treatment in oncology, and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in immunity.
It also develops PBP1510, a first-in-class antibody, which is in phase 1/2a clinical trial for the treatment of pancreatic cancer. Its portfolio also includes PBP1710, a first-in-class antibody that is in preclinical trials for the treatment of solid tumor and fibrosis, and IDC007, a bispecific antibody for the treatment of CRS. Additionally, it is developing IDC005, IDC001, IDC002, IDC003, IDC008, and IDC009 bispecific antibodies.
Its portfolio also includes IDC111, a first-in-class antibody, IDC112, first-in-class antibody, IDC113 first-in-class antibody, IDC332, IDC331, IDC333, and IDC334 novel concept antibodies, and IDC441, an ADC antibody for the treatment of solid tumours biosimilars for immunology, endocrinology, oncology, haematology, and dermatology diseases.
It also develops IDC221, a PAUF-based pancreatic cancer diagnostic solution for the treatment of pancreatic cancers. Incorporated in 2015, Prestige BioPharma is headquartered in Singapore.